IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Jun XuYa WangMina KhoshdeliMatt PeachJen-Chieh ChuangJulie LinWen-Wei TsaiSangeetha MahadevanWesley MintoLauri DiehlRuchi GuptaMichael TraunerKeyur PatelMazen NoureddinKris V KowdleyAliya GulamhuseinChristopher L BowlusRyan S HussRobert P MyersChuhan ChungAndrew N BillinPublished in: Hepatology (Baltimore, Md.) (2022)
IL-31 levels correlate with pruritus in patients with cholestatic disease and NASH, with FXR agonist therapy resulting in higher serum levels in the latter group. IL-31 appears to derive in part from increased hepatocyte expression. These findings have therapeutic implications for patients with liver disease and pruritus.